![](/wp-content/uploads/2022/11/November-10-2022-Blast-Cover.png)
$599
AZ and Zealand Q3 ’22 Earnings Updates; Novo Smart Pen Integration with Libre
Three cardiometabolic-related news items have been observed: AstraZeneca (press release; slides) and Zealand (press release; slides) hosted their Q3 ‘22 earnings calls, where Zealand talked about its dual agonist’s weight loss data; and Novo Nordisk announced its smart pens can now connect to Abbott’s FreeStyle LibreLink app in the UK. Below, FENIX provides context and insight on the respective news items.